Roper Technologies (ROP) Stock Could Be 19.5% Undervalued After Its 10.3% Dividend Hike

Roper Technologies (ROP) recently extended its multi decade dividend growth streak with a 10.3% increase, a move that highlights the company’s focus on shareholder returns despite leverage concerns and industry disruption.

See our latest analysis for Roper Technologies.

The recent dividend hike comes after a difficult period for Roper Technologies’ shareholders, with the share price down 22.37% year to date and the 1 year total shareholder return declining 39.57%. This comes despite a 5.12% 1 month share price gain, which may hint at stabilising sentiment.

If the Roper Technologies update has you reassessing your watchlist, this could be a useful moment to widen the lens and look at 20 top founder-led companies

So with Roper Technologies’ share price under pressure but trading at what some models suggest is a discount to intrinsic value, are you looking at an undervalued compounder here, or is the market already pricing in future growth?

Advertisement

Most Popular Narrative: 19.5% Undervalued

On the most followed narrative, Roper Technologies’ fair value of $419 sits above the last close of $337.33, which points to a clear valuation gap in the current share price.

The assumed bearish price target for Roper Technologies is $419.0, which represents up to two standard deviations below the consensus price target of $548.12. This valuation is based on what can be assumed as the expectations of Roper Technologies's future earnings growth, profit margins and other risk factors from analysts on the more bearish end of the spectrum.

Read the complete narrative.

Want to see what kind of revenue trajectory, margin profile and earnings power need to line up for that fair value? The narrative spells out a detailed earnings path, changing profitability and a tighter range of analyst expectations that all have to hold together for $419 to make sense.

Result: Fair Value of $419 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, Roper Technologies could surprise this bearish narrative if AI driven products like CentralReach and DAT scale faster than expected, or if acquisition synergies lift margins sooner.

Find out about the key risks to this Roper Technologies narrative.

Next Steps

With sentiment on Roper Technologies clearly mixed, take a moment to move past the headline and weigh both sides for yourself. Then review the full picture of 5 key rewards and 1 important warning sign

Looking for more investment ideas beyond Roper Technologies?

If Roper Technologies has your attention, do not stop there. Use the Simply Wall Street Screener to spot other opportunities that could suit your style.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

New: AI Stock Screener & Alerts

Our new AI Stock Screener scans the market every day to uncover opportunities.

• Dividend Powerhouses (3%+ Yield)
• Undervalued Small Caps with Insider Buying
• High growth Tech and AI Companies

Or build your own from over 50 metrics.

Explore Now for Free

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

About NasdaqGS:ROP

Roper Technologies

Designs and develops vertical software and technology enabled products in the United States, Canada, Europe, Asia, and internationally.

Undervalued with proven track record and pays a dividend.

Advertisement

Weekly Picks

LO
Lou_Basenese
OPTH logo
Lou_Basenese on Optimi Health ·

The Only Psychedelic Company Already Selling MDMA and Psilocybin to Real Patients, Yet Priced Like It Doesn’t Exist

Fair Value:US$1157.5% undervalued
47 users have followed this narrative
2 users have commented on this narrative
7 users have liked this narrative
WE
WealthAP
NOVO B logo
WealthAP on Novo Nordisk ·

Novo Nordisk (NVO): Is the "Easy Growth" Story Over?

Fair Value:DKK 407.7721.4% undervalued
68 users have followed this narrative
0 users have commented on this narrative
8 users have liked this narrative
VA
ValueInvestingSubstack
ZTS logo
ValueInvestingSubstack on Zoetis ·

Zoetis down -50% over the past year

Fair Value:US$92.9218.9% undervalued
23 users have followed this narrative
0 users have commented on this narrative
9 users have liked this narrative
CE
CentryResearch
LEU logo
CentryResearch on Centrus Energy ·

Centrus Energy: The Next Nuclear Bottleneck Isn't Reactors. It's Fuel.

Fair Value:US$19013.7% undervalued
24 users have followed this narrative
0 users have commented on this narrative
10 users have liked this narrative

Updated Narratives

WI
WisetoWealth
PYPL logo
WisetoWealth on PayPal Holdings ·

The Underrated Transformation of a Digital Payments Giant

Fair Value:US$90.3137.8% undervalued
2 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
BL
Blagget
TERA logo
Blagget on Terra Balcanica Resources ·

The C$4M Explorer Positioned to Become Europe's First Antimony Mine

Fair Value:CA$0.487.5% undervalued
2 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
DA
CHTR logo
david_6nroa on Charter Communications ·

Charter is undervalued - Here's why.

Fair Value:US$87.0741.6% overvalued
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative

Popular Narratives

CU
MSFT logo
CubanEros on Microsoft ·

A wonderful business at reasonable price.

Fair Value:US$419.919.1% undervalued
81 users have followed this narrative
0 users have commented on this narrative
6 users have liked this narrative
OS
oscargarcia
NVDA logo
oscargarcia on NVIDIA ·

The company that went from selling GPUs to gamers to becoming the AI arms dealer of the 21st century.

Fair Value:US$28026.1% undervalued
185 users have followed this narrative
9 users have commented on this narrative
15 users have liked this narrative
BE
PYPL logo
benjamin_lvieq on PayPal Holdings ·

PayPal: PayPal Doesn't Need to Grow – It Needs to Stop Falling – A Mispriced Cash Machine With a Cannibal Buyback

Fair Value:US$6513.6% undervalued
72 users have followed this narrative
2 users have commented on this narrative
11 users have liked this narrative

Trending Discussion

DE
TDOC logo
derek_3wsdg on Teladoc Health ·

You’ve overlooked the activist investor factor. Travis Cocke’s Voss has announced 5% ownership through a 13G filing. They’ve added to that 5% since, and in doing so, have created a structural trap door for 27.42 Million Shares actively sold short. Chuck will announce lots of positives on July 29 but it’s what Voss announces shortly after that will rock the overextended Teledoc shorts. The Walmart partnership is the tip of the iceberg. The market is missing the sheer regulatory and enterprise friction of modern corporate healthcare. Teladoc isn't a "consumer app"; it is the primary digital infrastructure integrated directly into the legacy backends of Tier-1 insurance companies and fortune 500 employers, covering 105 million+ lives. Teladoc is acting as the digital top-of-funnel engine for the world's largest retailer. If Voss pushes the narrative that Teladoc is effectively the outsourced digital brain of Walmart's entire healthcare footprint, the fair value shifts from a basic health multiple to an enterprise distribution premium. Additionally , we are in a structural gold rush for high-quality, legally compliant, longitudinal medical data to train vertical healthcare AI models. Large technology hyperscalers and pharmaceutical giants cannot simply scrape the internet for this; they need structured clinical inputs. Teladoc sits on one of the largest de-identified virtual medical datasets on earth. From the activist playbook , we’ll see Voss demand the immediate creation of a Data & Diagnostics Licensing Division, transforming a legacy liability into an incredibly high-margin, pure-software data asset that requires zero human clinician hours to scale. Chuck is doing great work and deserves credi5 for the Teledoc turnaround but it will be Travis Cocke who will be responsible for a share price way beyond your $15 valuation.

1
|
0